Samsung Biologics Corporate Brochure

Samsung Biologics, the leading end-to-end CDMO, is set to start building a new plant based in North Korea, to expand its biomanufacturing capabilties. 

Samsung Biologics has been awarded The Terra Carta Seal from the sustainable markets initiative.

Learn more about Samsung Biologics' Plant 4. Our accumulated expertise is implemented with the latest technologies and innovation, so that Plant 4 will be able to serve as part of your global presence.

In this interview with Jimin Han, Director of Climate Change in Business Strategy Team at Samsung Biologics (Incheon, South Korea), we discuss trends in the global biologics market, the biggest opportunities and challenges for this sector, and the growing consciousness surrounding sustainable practices for biologics developers and manufacturers.

We Make it Work - For Every Molecule


Successful development relies on a deep understanding of a molecule’s unique characteristics. At Samsung Biologics,we have the knowledge and expertise to realize the true potential of your molecule, regardless of its complexity. By takingthe right steps through our broad portfolio and platform processes, we help advance your molecule to IND and beyond.

With new drug approvals hitting a record high in 2021 and unprecedented number of out-licensing deals closed in 2020, Korean pharmaceutical companies and CDMO’s are poised for significant market growth [i].

A Trusted Navigator in Your Novel Path to Success- Forging Ahead. Together.
We offer mRNA drug substance and drug product manufacturing from a single site. Frequent handling of mRNA in multiple locations increases contamination and degradation risks, but when the entire work stream from pDNA to vial is coordinated by one partner from a single location, transitions across development and production tasks run smoothly,maximizing efficiency and eliminating these potential risks.

CDMO currently manufacturing LAAB combination treatment  and will start on cancer immunotherapy product from next year

The ultimate goal of aseptic fill/finish service is to ensure the safe delivery and administration of quality drug products (DP) to patients.  From our base at the center of an international bio-cluster, we enable clients to manufacture life-changing bio-therapeutics nearer to patients in need.

Watch this Learning Lab video presented by Chris McPherson, Principal Scientist, DS Manufacturing, Samsung Biologics, which details how CDMOs have reacted to the challenging ‘Black Swan’ event that is the COVID-19 pandemic by initiating ‘Green Swan’ thinking that is optimising timelines via agile execution, transparent communication and teamwork, and innovative regulatory strategy and support.

The choice for your next dual-specificity therapeutics

Samsung to provide end-to-end CDMO services to advance Kineta's novel anti-VISTA antibody for the treatment of solid tumours

Ensure success from an early stage

The CDMO will also provide IND filling support for KAHR's drug candidate DSP502

A company’s strategy is crucial for determining future success, and therefore, it needs to constantly change in line with market dynamics. Although building in-house offer the advantage of direct control, the time, labor, and spend required to implement this often makes it the inefficient choice. From this whitepaper, you will learn about the parameters to consider when selecting a CDMO.

The additional manufacturing suite at the CDMO's Songdo site is anticipated to be ready for cGMP operations within the first half of 2022

Manufacture The Future 

Imagine a future

Where ideas become cures

A future 
where innovation and technology 
help pioneer endless possibilities 
to make a lasting impact 

A future
Where efficiency meets expertise
Collaboration enables customizationDedication empowers breakthroughs

This is a place where we help your ingenuity 
to build a better future

A future we all want to live in.

Samsung Biologics

The CDMO will support the production of hundreds of millions of doses from its facility in Incheon, South Korea.

In recent years, the standardization of biologics manufacturing processes has given product developers multiple viable options for producing biologics. These options include building an in-house production system or partnering with a contract biologics manufacturer. Although building in-house does offer the advantage of direct control; the time, labor, and spend required to implement this often makes it the inefficient choice. On the other hand, working with an experienced contract manufacturer can help you save time and costs by leveraging a deep pool of industry experience. However, the process of selecting the right CDMO partner needs to be performed after careful analysis of many factors: any of which, if overlooked, can create risk of delay or cost overrun. In this session, we will discuss the key parameters that you can easily assess when choosing the right innovative CDMO partner that will keep you competitive in a rapidly evolving market.

Coronavirus pandemic has exacerbated manufacturing capacity constraints, particularly in injectable dose and viral vector production, CPHI audience told

Today, leading companies are not only centered on creating values, but they also focus on developing strategies to foster a company's longevity. Therefore, many companies have become more engaged in sustainable activities to make progress and are now joining the race. Acknowledging the importance of sustainable development, Biopharma CDMO companies are also finding ways to show their best performances in sustainability.
In this session, we will discuss the importance of why pharmaceutical CDMO companies should make their transition with long-term sustainability in mind. Explaining how the pharmaceutical industry (and innovative initiatives) should put effort into improving outcomes for patients, employees, the environment, and the wider community. Learn how Samsung Biologics, as one of the leading CDMO companies, is committed to making a sustainable future by creating ESG values through climate change responses, entry into the carbon neutral society, and transparency in the governance structure.

Plant 4 will add 256 KL capacity to its site, which is scheduled to commence manufacturing activities in the second half of 2022.